MedTrace Logo

Addition of 20mg/Day Zeaxanthin to Triple Therapy Treatment Options for Age Related Macular Degeneration (ARMD)

NCT01527435 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2016-04-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate the fact that 20 milligrams per day of oral Zeaxanthin as a supplement to patients with Choroidal neovascularization (CNV) and exudative age related macular degeneration (ARMD) undergoing combination therapy with intravitreal Bevacizumab (Avastin), intravitreal Dexamethasone and PDT laser photocoagulation and improves anatomic and visual outcome compared to patients not receiving oral Zeaxanthin. Study patients will be taking AREDS(PreserVision) and multivitamins (Centrum Silver); in addition one-half of the patients will receive 20mg of oral Zeaxanthin.

Conditions

  • Exudative Age-Related Macular Degeneration

Sponsors & Collaborators

  • ZeaVision, Inc.

    collaborator INDUSTRY

  • The Retina Center of St. Louis County, PC

    lead OTHER

Principal Investigators

  • Robert J Olk, MD · The Retina Center

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01527435 on ClinicalTrials.gov